SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the market weighs potential near-term rate cuts against longer-term economic concerns and Japan bond yield surge. Community members are actively discussing whether the recent AI-driven rally is sustainable, pointing to specific levels and potential downside risks, while some are anticipating a year-end rally.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending amid discussions about its AI strategy, particularly the AWS re:Invent conference and new AI chip developments that are intended to compete with Nvidia. The community is weighing the potential impact of these innovations on Amazon's market position and profitability, along with its ongoing partnerships. Some are concerned over high spending and performance, while others express optimism about long-term cloud and AI growth.

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Polyrizon Ltd. Ordinary Shares

PLRZ is trending due to positive preclinical data for its intranasal naloxone hydrogel, with the community actively debating whether the stock will continue to squeeze or face dilution. The stock's low float and previous reverse splits are fueling volatility, while some traders are drawing comparisons to similar plays like $SMX and anticipating a potential multi-day run.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending amid discussions about its recent earnings beat and future prospects in the AI automation space; the community is weighing in on whether the company can sustain growth and capitalize on its partnerships with major tech players. Some traders are highlighting the high short interest and potential for a squeeze, while others focus on long-term potential and the stock's undervaluation relative to its peers. Discussions also include the upcoming fireside chat at the Barclays Global Technology Conference.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community discusses potential bullish formations, historical transactional advantages, and potential for a spot ETF. Some speculate on an upcoming golden cross and a breakout against Bitcoin, while others express frustration with its historical performance. Discussions also highlight Litecoin's reliability for payments and potential role in the digital silver narrative.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as community members discuss its AI initiatives, particularly the Gemini model and TPU technology, and speculate on potential partnerships. Some traders are noting technical indicators and option activity, while others assess its competitive positioning against key players like NVDA. The stock's potential to reach a $4 trillion market cap is also being debated.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

BRK.B is trending amid discussion of its massive cash reserves and strong Q3 earnings, with operating profits surging. Community chatter revolves around Berkshire's strategy given the current market conditions, particularly regarding potential acquisitions or share buybacks. Some investors view BRK.B as a safe haven during market uncertainty, while others question its valuation and future performance post-Buffett.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to positive Phase 3 data for their DMD treatment, sparking buyout speculation and a potential short squeeze. The community is buzzing about the implications for FDA approval and the possibility of partnerships with larger pharmaceutical companies. However, some traders express skepticism, citing past FDA setbacks and statistical significance concerns.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 2x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending as traders weigh market volatility amid economic data and global events. Community members are actively discussing potential market corrections, hedging strategies, and the impact of quantitative tightening. The upcoming reverse split is also a key point of discussion, with some traders expressing concerns about its impact on options.

Moonriver is a fully Ethereum-compatible smart contract parachain on Kusama. Due to this Ethereum-like design and developer-friendly approach, Moonriver has attracted dozens of projects to build on it: https://moonbeam.network/community/projects/. It does this by providing a full EVM implementation, a Web3-compatible API, and bridges that connect Moonriver to existing Ethereum networks. This allows developers to deploy existing Solidity/Vyper smart contracts and DApp frontends to Moonriver with minimal changes.  It is intended to be a companion network to Moonbeam (on Polkadot), where it will provide a permanently incentivized canary network. New code will ship to Moonriver first, where it can be tested and verified under real economic conditions. Once proven, the same code will ship to Moonbeam on Polkadot.

Moonriver

Moonriver is trending as community members discuss its potential for significant gains, drawing comparisons to past surges and highlighting its low supply. Some are speculating on future listings and its relationship to the Polkadot ecosystem. Technical analysis and staking opportunities are also being actively discussed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of ZyVersa Therapeutics surged Wednesday, drawing heavy attention from retail investors after the company unveiled new plans to position its inflammasome ASC inhibitor, IC 100, as an adjunct to GLP-1 receptor agonists in addressing obesity-related cardiometabolic complications.The stock closed up&nbsp;over 24% at $0.68 on Wednesday before paring gains in after-hours trading, falling 12.38% to $0.60.In a shareholder letter, CEO Stephen C. Glover outlined a strategy to target inflammation-driven pathways that remain unaddressed by GLP-1 agonists such as semaglutide.&nbsp;While these drugs have transformed obesity treatment by inducing significant weight loss, Glover pointed to high discontinuation rates — up to 85% within two years among non-diabetic patients—and side effects including muscle loss and gastrointestinal issues as key limitations.“While GLP-1 agonists have revolutionized obesity treatment, significant unmet medical needs remain,” Glover wrote.ZyVersa’s IC 100 targets ASC and ASC specks, which play a central role in initiating and perpetuating inflammasome activation.&nbsp;Unlike most inflammasome inhibitors in development that target NLRP3, IC 100 is designed to broadly inhibit several inflammasomes implicated in obesity, insulin resistance, and diabetic nephropathy, including AIM2, NLRP1, NLRC4, and others.Preclinical studies cited by the company demonstrated that IC 100 reduced inflammation and plaque formation in an ApoE knockout model of atherosclerosis, lowered fasting blood glucose in diabetic kidney disease models, and suppressed key proinflammatory cytokines such as IL-1β, IL-18, and IL-6.ZyVersa said it will initiate a preclinical study combining IC 100 with semaglutide in H1 2025, file an Investigational New Drug (IND) application in H2 2025, and begin Phase 1 clinical trials in H1 2026 focusing on overweight individuals with cardiometabolic risk factors.Retail sentiment surged on Stocktwits, where message volume was marked “extremely high” and sentiment labeled “extremely bullish.”&nbsp;One user speculated the stock could rally to $2, while another suggested it looked “set up nicely” to retest the $1.05 pre-market high.<stembedurl>https://stocktwits.com/Netplus1/message/613838869</stembedurl><stembedurl>https://stocktwits.com/Chrismg8/message/613837620</stembedurl>Shares of Zyversa have fallen 37.2% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

One user thought Viking's stock "should be up 30-40%" as it has the "best in class oral GLP-1 now."

Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps

ZyVersa's IC 100 strategy focuses on targeting inflammasome-driven inflammation to enhance weight loss and improve metabolic function in obesity patients. 

Equity

Peering Into ZyVersa Therapeutics's Recent Short Interest

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide.The published data...

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA  Get Free Report) saw a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 646,000 shares...

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024.Inflammasome ASC Inhibitor IC 100 preclinical...

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator  VAR 200 in Patients with Diabetic Kidney Disease

Phase 2a trial is on track to begin in the first half of 2024.Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration...

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled  Inflammation Illuminated, at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024

According to the World Health Organization, 3 of 5 people worldwide die due to chronic inflammatory diseases, which are considered the most significant cause of death in the world.ZyVersa is...

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Growth in Short Interest

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA  Get Free Report) was the target of a large growth in short interest in February. As of February 29th, there was short interest totalling 1,190,000...

ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity

ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which is designed to inhibit formation of multiple types of inflammasomes, including NLRP3, and their associated ASC specks to attenuate...

ZyVersa Therapeutics highlights data from publication on IC 100

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.

Current Price	$0.1361
Prev Close	$0.1336
Open	$0.1369
Dividend Yield	0.00%
50-Day Moving Average	$0.1459
Beta	0.39
Avg. Volume	43,308.84
PE Ratio	-0.03

52-Week High	$1.95
52-Week Low	$0.11
Market Capitalization	$1.08M
EPS (Annual)	-$8.48
Price to Book	-0.09
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ZVSA
ZyVersa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ZVSA News

ZVSAZyVersa Therapeutics Inc